SIRT2 and cancer: The tumor suppressive effect of DCA or Nic combination regimens has been demonstrated in xenografts of different cancer types: DCA/activated natural killer cells/anti-CD20 (Belkahla et al., 2022), DCA/4‐methylumbelliferone (Twarock et al., 2019), DCA/arginase (Verma et al., 2019), DCA/sirtinol (SIRT2 inhibitor) (Ma et al., 2018), DCA/cisplatin (Woolbright et al., 2018), Nic/cisplatin (Liu et al., 2021) and Nic/paclitaxel (Chen et al., 2017).